Literature DB >> 21958534

Central glucocorticoid receptor-mediated effects of the antidepressant, citalopram, in humans: a study using EEG and cognitive testing.

Carmine M Pariante1, Hamid A Alhaj, Vijay Edmund Arulnathan, Peter Gallagher, Andy Hanson, E Massey, R Hamish McAllister-Williams.   

Abstract

Our previous work in cellular and animal models has shown that antidepressants activate glucocorticoid receptor (GR) translocation, induce GR down-regulation, and decrease GR-mediated effects in the presence of GR agonists. However, whether these effects can be extrapolated to the human brain is still unclear. In this study, the effects of four days of treatment with the antidepressant, citalopram (20 mg/day), or placebo, were assessed in a double-blind, placebo-controlled, cross-over study. Central GR-mediated effects were examined by the effects of a single dose of cortisol (30 mg, orally) on two measures known to be sensitive to glucocorticoid administration: EEG alpha power and working memory function. Twenty healthy male subjects aged between 18 and 33 years participated to the study. The results suggest that GR activation by antidepressants, and the subsequent decrease in GR-mediated effects in the presence of GR agonists, indeed occurs in the human brain. Specifically, pre-treatment with citalopram decreased the well-known ability of cortisol to increase EEG alpha power and to impair working memory: cortisol-induced increase in EEG alpha power was (anteriorly) +15 to +20% (p=0.01) after placebo and +5 to +8% (p>0.5) after citalopram; and cortisol-induced increase in working memory errors was (at level 12, on average) 2.50 vs. 4.55 (p<0.05) after placebo and 4.10 vs. 3.35 (p>0.05) after citalopram. No effects were detected on alerting. These results are consistent with the notion that citalopram treatment activates GR translocation and inhibits the functional consequences of the subsequent cortisol administration. Our study further emphasizes the importance of the GR as a target for antidepressant action in humans. Copyright Â
© 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21958534     DOI: 10.1016/j.psyneuen.2011.08.011

Source DB:  PubMed          Journal:  Psychoneuroendocrinology        ISSN: 0306-4530            Impact factor:   4.905


  11 in total

1.  HPA-axis function, symptoms, and medication exposure in youths at clinical high risk for psychosis.

Authors:  G Sugranyes; J L Thompson; C M Corcoran
Journal:  J Psychiatr Res       Date:  2012-08-11       Impact factor: 4.791

2.  Resting cortisol level, self-concept, and putative familial environment in adolescents at ultra high-risk for psychotic disorders.

Authors:  Emily E Carol; Vijay A Mittal
Journal:  Psychoneuroendocrinology       Date:  2015-03-28       Impact factor: 4.905

3.  Ketamine, but not fluoxetine, rapidly rescues corticosterone-induced impairments on glucocorticoid receptor and dendritic branching in the hippocampus of mice.

Authors:  Daiane B Fraga; Anderson Camargo; Gislaine Olescowicz; Dayane Azevedo Padilha; Francielle Mina; Josiane Budni; Patricia S Brocardo; Ana Lúcia S Rodrigues
Journal:  Metab Brain Dis       Date:  2021-05-05       Impact factor: 3.584

4.  Cortisol effects on brain functional connectivity during emotion processing in women with depression.

Authors:  Charlene N Rivera-Bonet; Rasmus M Birn; Charlotte O Ladd; Mary E Meyerand; Heather C Abercrombie
Journal:  J Affect Disord       Date:  2021-03-19       Impact factor: 4.839

5.  Candidate genes expression profile associated with antidepressants response in the GENDEP study: differentiating between baseline 'predictors' and longitudinal 'targets'.

Authors:  Annamaria Cattaneo; Massimo Gennarelli; Rudolf Uher; Gerome Breen; Anne Farmer; Katherine J Aitchison; Ian W Craig; Christoph Anacker; Patricia A Zunsztain; Peter McGuffin; Carmine M Pariante
Journal:  Neuropsychopharmacology       Date:  2012-09-19       Impact factor: 7.853

6.  How does intentionality of encoding affect memory for episodic information?

Authors:  Michael Craig; Karla Butterworth; Jonna Nilsson; Colin J Hamilton; Peter Gallagher; Tom V Smulders
Journal:  Learn Mem       Date:  2016-10-17       Impact factor: 2.460

7.  A parallel universe where psychiatry is like the rest of medicine.

Authors:  C M Pariante
Journal:  Epidemiol Psychiatr Sci       Date:  2017-12-04       Impact factor: 6.892

8.  Glucocorticoid-related molecular signaling pathways regulating hippocampal neurogenesis.

Authors:  Christoph Anacker; Annamaria Cattaneo; Alessia Luoni; Ksenia Musaelyan; Patricia A Zunszain; Elena Milanesi; Joanna Rybka; Alessandra Berry; Francesca Cirulli; Sandrine Thuret; Jack Price; Marco A Riva; Massimo Gennarelli; Carmine M Pariante
Journal:  Neuropsychopharmacology       Date:  2012-12-06       Impact factor: 7.853

Review 9.  Depression pathogenesis and treatment: what can we learn from blood mRNA expression?

Authors:  Nilay Hepgul; Annamaria Cattaneo; Patricia A Zunszain; Carmine M Pariante
Journal:  BMC Med       Date:  2013-02-05       Impact factor: 8.775

10.  Study protocol for the randomised controlled trial: antiglucocorticoid augmentation of anti-Depressants in Depression (The ADD Study).

Authors:  R Hamish McAllister-Williams; Eleanor Smith; Ian M Anderson; Jane Barnes; Peter Gallagher; Heinz C R Grunze; Peter M Haddad; Allan O House; Tom Hughes; Adrian J Lloyd; Elaine M M McColl; Simon H S Pearce; Najma Siddiqi; Baxi Sinha; Chris Speed; I Nick Steen; June Wainright; Stuart Watson; Fiona H Winter; I Nicol Ferrier
Journal:  BMC Psychiatry       Date:  2013-08-03       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.